Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)

Osaka University

Status

Completed

Conditions

Dementia With Lewy Bodies (DLB)

Treatments

Drug: Donepezil

Study type

Interventional

Funder types

Other

Identifiers

NCT00776347

OSK-08096

Details and patient eligibility

About

The purpose of this study is to evaluate change of cerebral glucose metabolism by donepezil therapy and to associate change of glucose metabolism and symptoms.

Enrollment

24 patients

Sex

All

Ages

60 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

DLB patients:

who fulfill the diagnostic criteria of DLB
60 to 85 years old
right-handed
Clinical Dementia Rating (CDR) ≧ 0.5
Mini Mental State Examination (MMSE) score from 10 to 26

Normal Controls:

who are independent
who have no subjective or objective cognitive impairment
60 to 85 years old
right-handed
MMSE score over 24

Exclusion criteria

DLB patients:

who have diabetes mellitus
who have pathological change on MRI other than brain atrophy
who have complication or history of dementia other than DLB, psychiatric disease, and physical disorder that affect brain function
who have severe complication of cardiovascular, hepatic, renal, or other diseases unable to secure the safety
who have severe digestive ulcus
who have severe bronchitic asthma or obstructive lung disease
who have no caregiver who knows patient's condition well

Normal Controls:

who have diabetes mellitus
who have taken donepezil before
who have abnormal findings on MRI
who have complication or history of brain injury, psychiatric disease, and physical disorder that affect brain function